To report on the activity of hematopoietic cell transplants (HCT) and CAR-T therapies in 2024, highlighting significant trends and milestones in cellular therapy that impact clinical practices.
Key Findings:
In 2024, a total of 47,204 HCTs were reported, with 21,023 allogeneic and 26,181 autologous transplants, reflecting the ongoing evolution of HCT practices.
CAR-T therapy reached 6,082 patients, marking a 24.5% increase from 2023 and surpassing 20,000 therapies since 2018, indicating a significant growth in this treatment modality.
Main indications for allo-HCT included myeloid malignancies (62%), lymphoid malignancies (~24%), and non-malignant disorders (~17%), showcasing the diverse applications of HCT.
For auto-HCT, plasma cell disorders accounted for 59%, lymphomas for 22%, and solid tumors for ~6%, highlighting the primary conditions treated with this approach.
Unrelated donor usage increased to 56%, while cord blood use decreased by 6.2%, reflecting changing trends in donor selection.
Interpretation:
The survey indicates a steady increase in HCT and CAR-T activity, despite a slight overall decline in total HCT and autologous procedures in 2024, which may suggest shifts in treatment preferences or patient populations.
Limitations:
Data from 54 centres was not submitted, potentially affecting overall HCT numbers and the reliability of trends observed.
The survey's focus on European and collaborating countries may limit the generalizability of findings to other regions.
Conclusion:
The EBMT survey has surpassed one million HCTs and shows significant growth in CAR-T therapies, reflecting the evolving landscape of cellular treatments and emphasizing the need for ongoing research and adaptation in clinical practice.
by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda
